Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose placebo-controlled study of SPC3649 in healthy volunteers
NL-OMON33484Active, not recruiting
- Sponsor
- Santaris Pharma
- Start
- Sep 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in hepatitis C virus infection comparing SPC3649 with Placebo (2 arms). Primary endpoint: Safety and tolerability of multiple dosing of SPC3649. Started Sep 2009; status: active, not recruiting.
02
Drugs
miravirsen
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON33484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33484.